Fate Therapeutics develops off-the-shelf cell therapies using a proprietary platform based on induced pluripotent stem cells (iPSCs). Master iPSC lines are engineered and expanded to produce consistent batches of NK and T cell products for treating cancer and autoimmune diseases. This approach enables scalable, standardized immunotherapies intended to address limitations of patient-derived cell treatments.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1.6 | — | -37.6 | — |
| Q2 2025 | 1.9 | — | -34.1 | — |
| Q3 2025 | 1.7 | — | -32.3 | — |
| Q4 2025 | 1.4 | — | -32.4 | — |
| Q1 2026 | 1.3 | -20.3% | -31.2 | — |
| Q2 2026 | 2.1 | 9.2% | -30.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Aeon Acquisition I Corp. (AESP), Niagen Bioscience, Inc. (NAGE), Gorilla Technology Group Inc. (GRRR), Zumiez Inc. (ZUMZ), Lightbridge Corporation (LTBR), Z Squared Inc. (ZSQR)